(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)
Abbott introduces delivery system for electrode implantation process
Abbott has introduced a next-generation delivery system for its Proclaim DRG neurostimulation therapy, aiming to simplify electrode implantation and enhance treatment for complex regional pain syndrome (CRPS) types 1 and 2. The Proclaim DRG system, which includes an implantable pulse generator and stimulation leads, is the first and only DRG-targeted technology approved for treating lower limb CRPS.
By delivering targeted electrical impulses to the dorsal root ganglion—a nerve cell cluster along the spine responsible for transmitting pain signals from areas like the hip and foot—the therapy helps disrupt pain communication. According to Abbott, 80% of users experience significant pain relief, averaging an 81% reduction in intensity.
The new delivery system is engineered for better control and durability, aiding precise lead placement through image-guided navigation. Research supports DRG stimulation’s superiority over traditional spinal cord stimulation for CRPS, and Abbott continues to refine the technology to expand access and improve patient outcomes.
08-04-2025